Weifa ASA : Record revenues in the fourth quarter

Oslo, 19 February 2016

Weifa ASA: Record revenues in the fourth quarter

            ·         All time high revenues in fourth quarter 2015 of NOK 97.6 million (NOK 90.5 million)

            ·         EBITDA margin of 22.6%

            ·         Strong cash flow from operating activities

            ·         Full-year revenues rose 5.6%

            ·         Strong brands secured high market share in all categories and segments of both channels

            ·         Asan acquisition, adding the leading Norwegian intimate care brand to the Weifa portfolio

            ·         Weifa expects full-year 2016 organic revenue growth and improved EBITDA margin

Weifa ASA (OSE: WEIFA) had record revenues in the fourth quarter 2015 with increased sales in all categories.  Total revenue for the quarter was NOK 97.6 million, representing an increase of 7.9% compared with the year earlier period. Weifa maintained high market share in all key segments during the quarter, and delivered continued good operations.

EBITDA was NOK 24.4 million, before NOK 2.4 million in the calculated cost of employee options and costs in conjunction with the acquisition of Cederroth AS and the Asan portfolio, corresponding to an adjusted EBITDA margin of 25%.

Total consumer health revenue for the year 2015 was NOK 332.5 million, representing an increase of 5.6 percent from 2014. Full-year EBITDA came to NOK 72.9 million before option- and other costs of NOK 7.3 million, corresponding to an adjusted EBITDA margin of 22%.

"Weifa delivered revenue growth and improved EBITDA margin through 2015 while at the same time becoming a pure consumer health company and in the fourth quarter announcing the acquisition of the leading intimate care brand Asan.  We have extended our platform of flagship brands as we move into 2016 and target continued organic growth and improved EBITDA margin", says CEO Kathrine Gamborg Andreassen.

Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from:

http://webtv.hegnar.no/presentation.php?webcastId=29501347 or

http://www.weifa.no/webcast/

Please find the report and presentation for the fourth quarter enclosed. The report and presentation will also be made available on www.weifa.no.

For further information, please contact:

Kathrine Gamborg Andreassen

CEO

+47 95 17 86 80

kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen

CFO

+47 98 20 63 55

Simen.nyberg-hansen@weifa.no

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no